zanzalintinib
zanzalintinib: developed by 1 company · 24 clinical trials tracked.
zanzalintinib evidence translation
What we can confirm
24 tracked trials
What it means
What to watch
Prepared research question
How could zanzalintinib → EXEL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| EXELIXIS, INC. (EXEL) Pancreatic Neuroendocrine Tumor (pNET); Renal Cell Carcinoma… | Phase 3 |
Clinical Trials (24)showing 10 most recent
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Primary endpoint: Objective Response Rate (ORR)
A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLTs)
ZENITH: Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Radiographic progression free survival (rPFS)
Phase II Study of Zanzalintinib in Men With Aggressive Variant Prostate Cancer (NAPOLEON Study)
Primary endpoint: Radiographic progression free survival (rPFS)
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy
Primary endpoint: Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors
Primary endpoint: Proportion of participants who have not progressed at 12 months (PFS12)
Phase II Trial of Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Primary endpoint: Objective response rate (ORR)
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Primary endpoint: Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)
A Phase II Study of Maintenance Zanzalintinib and Durvalumab in Patients With Advanced Hepatocellular Cancer After Induction Tremelimumab Plus Durvalumab
Primary endpoint: Progression-Free Survival (PFS) at 16 weeks
Frequently asked questions
Who is developing zanzalintinib?
zanzalintinib is being developed by EXELIXIS, INC..
How many clinical trials involve zanzalintinib?
BioSniper tracks 24 clinical trials involving zanzalintinib.